Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sertraline for prevention of depression after traumatic brain injury
ISRCTN17518945Phase 3Completed
- Sponsor
- King's College Hospital
- Start
- Feb 2023
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Treatment as usual plus placebo with Treatment as usual plus sertraline (2 arms). Primary endpoint: Depressive symptoms at 12 months. Started Feb 2023; status: completed.
02
Drugs
sertraline
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ISRCTN17518945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN17518945.